TimesSquare Capital Management LLC Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TimesSquare Capital Management LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 31.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 193,516 shares of the company's stock after buying an additional 46,857 shares during the quarter. IDEXX Laboratories accounts for 1.2% of TimesSquare Capital Management LLC's investment portfolio, making the stock its 24th largest holding. TimesSquare Capital Management LLC owned 0.24% of IDEXX Laboratories worth $80,007,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after acquiring an additional 40,349 shares during the period. Franklin Resources Inc. grew its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after purchasing an additional 34,305 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after purchasing an additional 2,463 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after buying an additional 316,048 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on IDXX shares. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Trading Up 1.3 %

Shares of IDEXX Laboratories stock traded up $5.94 during mid-day trading on Friday, hitting $458.80. 36,178 shares of the stock were exchanged, compared to its average volume of 684,576. The stock has a market capitalization of $37.57 billion, a price-to-earnings ratio of 42.88, a price-to-earnings-growth ratio of 3.39 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a 50-day simple moving average of $431.50 and a 200 day simple moving average of $452.42.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.